HOW SUPPLIED SECTION.


16 HOW SUPPLIED/STORAGE AND HANDLING VUITY is supplied as sterile ophthalmic solution in colorless low density polyethylene (LDPE) ophthalmic dispenser bottles and tips, with dark green high impact polystyrene caps as follows:2.5 mL fill in mL bottle (Box containing bottle)NDC 0074-7098-012.5 mL fill in mL bottle (Box containing bottles)NDC 0074-7098-032.5 mL fill in mL bottle (Carton)NDC 0074-7098-04StorageStore at 15C to 25C (59F to 77F). After opening, VUITY can be used until the expiration date on the bottle.

INDICATIONS & USAGE SECTION.


1 INDICATIONS AND USAGE. VUITY is indicated for the treatment of presbyopia in adults.. VUITY is cholinergic muscarinic receptor agonist indicated for the treatment of presbyopia in adults. (1).

SPL UNCLASSIFIED SECTION.


5.1 Poor Illumination. Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

ADVERSE REACTIONS SECTION.


6 ADVERSE REACTIONS. The following clinically significant adverse reactions are described elsewhere in labeling:Hypersensitivity [see Contraindications 4 )] Hypersensitivity [see Contraindications 4 )] Most common adverse reactions (>5%) are headache and conjunctival hyperemia. (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.VUITY was evaluated in 375 patients with presbyopia in two randomized, double-masked, vehicle-controlled studies (GEMINI and GEMINI 2) of 30 days duration. The most common adverse reactions reported in >5% of patients were headache and conjunctival hyperemia. Ocular adverse reactions reported in 1-5% of patients were blurred vision, eye pain, visual impairment, eye irritation, and increased lacrimation.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.


13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisPilocarpine did not induce tumors in mice at any dosage level studied (up to 30 mg/kg/day; approximately 160-times the MRHOD). In rats, an oral dose of 18 mg/kg/day (approximately 200 times the MRHOD), resulted in statistically significant increase in the incidence of benign pheochromocytomas in both male and female rats, and statistically significant increase in the incidence of hepatocellular adenomas in female rats. MutagenesisPilocarpine did not show any potential to cause genetic toxicity in series of studies that included: 1) bacterial assays (Salmonella and E. coli) for reverse gene mutations; 2) an in vitro chromosome aberration assay in Chinese hamster ovary cell line; 3) an in vivo chromosome aberration assay (micronucleus test) in mice; and 4) primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures.Impairment of FertilityPilocarpine oral administration to male and female rats at dosage of 18 mg/kg/day (200 times the recommended human daily dose) resulted in impaired reproductive function, including reduced fertility, decreased sperm motility, and morphologic evidence of abnormal sperm. It is unclear whether the reduction in fertility was due to effects on males, females, or both. In dogs, exposure to pilocarpine at dosage of mg/kg/day for months resulted in evidence of impaired spermatogenesis (approximately 110 times the recommended human daily dose).

CLINICAL PHARMACOLOGY SECTION.


12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Pilocarpine hydrochloride is cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. VUITY contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. VUITY also contracts the ciliary muscle and may shift the eye to more myopic state.. 12.3 Pharmacokinetics. Systemic exposure to pilocarpine was evaluated in 22 participants with presbyopia who were administered drop of VUITY in each eye once daily for 30 days. The mean Cmax and AUC0- t,ss values on Day 30 were 1.95 ng/mL and 4.14 ng.hr/mL, respectively. The median Tmax value on Day 30 was 0.3 hours postdose with range from 0.2 to 0.5 hours postdose.

CLINICAL STUDIES SECTION.


14 CLINICAL STUDIES. The efficacy of VUITY for the treatment of presbyopia was demonstrated in two 30-Day Phase 3, randomized, double-masked, vehicle-controlled studies, namely GEMINI (NCT03804268) and GEMINI (NCT03857542). total of 750 participants aged 40 to 55 years old with presbyopia were randomized (375 to VUITY group) in two studies and participants were instructed to administer one drop of VUITY or vehicle once daily in each eye. In both studies, the proportion of participants gaining lines or more in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA), without losing more than line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction was statistically significantly greater in the VUITY group compared to the vehicle group at Day 30, Hour (see Table 1). Table 1: Primary Efficacy Results from GEMINI and GEMINI Studies (Intent-to-Treat Population)GEMINI 1GEMINI 2VUITY N=163Vehicle N=160p-valueVUITYN=212Vehicle N=215p-valueProportion of participants gaining 3-lines or more in mesopic DCNVA, without losing more than line (5 letters) of CDVA at Day 30, Hour 31% 8%p<0.0126% 11%p<0.01Figures and present the proportion of participants who gained 3-lines or more in mesopic DCNVA at Day 30. Figure 1: Proportion of Participants Achieving 3-Lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI (Intent-to-Treat Population)Figure 2: Proportion of Participants Achieving 3-lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI (Intent-to-Treat population). Figure 1: Proportion of Participants Achieving 3-Lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI (Intent-to-Treat Population). Figure 2: Proportion of Participants Achieving 3-lines or More Improvement in Mesopic, High Contrast, Binocular DCNVA at Day 30 in GEMINI (Intent-to-Treat population).

CLINICAL TRIALS EXPERIENCE SECTION.


6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.VUITY was evaluated in 375 patients with presbyopia in two randomized, double-masked, vehicle-controlled studies (GEMINI and GEMINI 2) of 30 days duration. The most common adverse reactions reported in >5% of patients were headache and conjunctival hyperemia. Ocular adverse reactions reported in 1-5% of patients were blurred vision, eye pain, visual impairment, eye irritation, and increased lacrimation.

CONTRAINDICATIONS SECTION.


4 CONTRAINDICATIONS. VUITY is contraindicated in patients with known hypersensitivity to the active ingredient or to any of the excipients.. Hypersensitivity (4).

DESCRIPTION SECTION.


11 DESCRIPTION VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is cholinergic muscarinic receptor agonist prepared as an isotonic, colorless, sterile ophthalmic solution containing 1.25% of pilocarpine hydrochloride. The chemical name for pilocarpine hydrochloride is (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]oxolan-2-one hydrochloride. Its molecular weight is 244.72 and its molecular formula is C11H16N2O2 HCl. Its structural formula is:Each mL of VUITY contains pilocarpine hydrochloride 1.25% (12.5 mg) as the active ingredient, equivalent to 1.06% (10.6 mg) pilocarpine free-base. Preservative is: benzalkonium chloride 0.0075%. Inactive ingredients in the ophthalmic solution are: boric acid, sodium citrate dihydrate, sodium chloride, purified water, and may also include hydrochloric acid and/or sodium hydroxide for pH adjustment to between 3.5 and 5.5, if necessary. structural formula.

DOSAGE & ADMINISTRATION SECTION.


2 DOSAGE AND ADMINISTRATION. The recommended dosage of VUITY is one drop in each eye once daily.If more than one topical ophthalmic product is being used, the products should be administered at least minutes apart.. Instill one drop of VUITY in each eye once daily. (2).

DOSAGE FORMS & STRENGTHS SECTION.


3 DOSAGE FORMS AND STRENGTHS. VUITY (pilocarpine hydrochloride ophthalmic solution) is provided as 1.25% solution (12.5 mg/mL).. Ophthalmic solution containing pilocarpine hydrochloride 1.25%. (3).

GERIATRIC USE SECTION.


8.5 Geriatric Use. Clinical studies of VUITY did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience with ophthalmic pilocarpine solutions have not identified overall differences in safety between elderly and younger patients.

INFORMATION FOR PATIENTS SECTION.


17 PATIENT COUNSELING INFORMATION. Night DrivingCaution is advised with night driving and when hazardous activities are undertaken in poor illumination. [see Warnings and Precautions 5.1 )] Accommodative Spasm Temporary problems when changing focus between near objects and distant objects may occur. Advise patients not to drive or use machinery if vision is not clear. [see Warnings and Precautions 5.1 )] When to Seek Physician Advice Advise patients to seek immediate medical care with sudden onset of vision loss. [see Warnings and Precautions 5.2 )] Contact Lens WearContact lens should be removed prior to the instillation of VUITY. Wait 10 minutes after dosing before reinserting contact lenses. [see Warnings and Precautions 5.4 )] Avoiding Contamination of the ProductDo not touch dropper tip to any surface, as this may contaminate the contents. [see Warnings and Precautions 5.5 )] Concomitant Topical Ocular TherapyIf more than one topical ophthalmic medication is being used, the medicines must be administered at least minutes apart.Distributed by: Allergan, an AbbVie Company Manufactured for:AbbVie Inc. North Chicago, IL 60064 USA Allergan is an affiliate of AbbVie Inc. (C) 2021 Allergan, an AbbVie Company. North Chicago, IL, 60064, USA Patented. v1.0USPI7098. Allergan.

LACTATION SECTION.


8.2 Lactation Risk SummaryThere is no information regarding the presence of pilocarpine in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of VUITY to an infant during lactation. Pilocarpine and/or its metabolites are excreted in the milk of lactating rats. Systemic levels of pilocarpine following topical ocular administration are low [see Clinical Pharmacology 12.3 ], and it is not known whether measurable levels of pilocarpine would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for VUITY and any potential adverse effects on the breastfed child from VUITY.DataAnimal DataFollowing single oral administration of 14C-pilocarpine to lactating rats, the radioactivity concentrations in milk were similar to those in plasma.

MECHANISM OF ACTION SECTION.


12.1 Mechanism of Action. Pilocarpine hydrochloride is cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. VUITY contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light. VUITY also contracts the ciliary muscle and may shift the eye to more myopic state.

NONCLINICAL TOXICOLOGY SECTION.


13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. CarcinogenesisPilocarpine did not induce tumors in mice at any dosage level studied (up to 30 mg/kg/day; approximately 160-times the MRHOD). In rats, an oral dose of 18 mg/kg/day (approximately 200 times the MRHOD), resulted in statistically significant increase in the incidence of benign pheochromocytomas in both male and female rats, and statistically significant increase in the incidence of hepatocellular adenomas in female rats. MutagenesisPilocarpine did not show any potential to cause genetic toxicity in series of studies that included: 1) bacterial assays (Salmonella and E. coli) for reverse gene mutations; 2) an in vitro chromosome aberration assay in Chinese hamster ovary cell line; 3) an in vivo chromosome aberration assay (micronucleus test) in mice; and 4) primary DNA damage assay (unscheduled DNA synthesis) in rat hepatocyte primary cultures.Impairment of FertilityPilocarpine oral administration to male and female rats at dosage of 18 mg/kg/day (200 times the recommended human daily dose) resulted in impaired reproductive function, including reduced fertility, decreased sperm motility, and morphologic evidence of abnormal sperm. It is unclear whether the reduction in fertility was due to effects on males, females, or both. In dogs, exposure to pilocarpine at dosage of mg/kg/day for months resulted in evidence of impaired spermatogenesis (approximately 110 times the recommended human daily dose).

OVERDOSAGE SECTION.


10 OVERDOSAGE. Systemic toxicity following topical ocular administration of pilocarpine is rare, but occasionally patients who are sensitive may develop sweating and gastrointestinal overactivity. Accidental ingestion can produce sweating, salivation, nausea, tremors and slowing of the pulse and decrease in blood pressure. In moderate overdosage, spontaneous recovery is to be expected and is aided by intravenous fluids to compensate for dehydration. For patients demonstrating severe poisoning, atropine, the pharmacologic antagonist to pilocarpine, should be used.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.


PRINCIPAL DISPLAY PANEL. NDC 0074-7098-01Vuity(TM) (pilocarpine HCI ophthalmic solution) 1.25%Contains one 2.5 mL bottleRx OnlySterileFor topical application in the eye1 2.5 mLAllergan(TM)An AbbVie company. PRINCIPAL DISPLAY PANELNDC 0074-7098-01Vuity(TM) (pilocarpine HCI ophthalmic solution) 1.25%Contains one 2.5 mL bottleRx OnlySterileFor topical application in the eye1 2.5 mLAllergan(TM)An AbbVie company.

PEDIATRIC USE SECTION.


8.4 Pediatric Use. Presbyopia does not occur in the pediatric population.

PHARMACOKINETICS SECTION.


12.3 Pharmacokinetics. Systemic exposure to pilocarpine was evaluated in 22 participants with presbyopia who were administered drop of VUITY in each eye once daily for 30 days. The mean Cmax and AUC0- t,ss values on Day 30 were 1.95 ng/mL and 4.14 ng.hr/mL, respectively. The median Tmax value on Day 30 was 0.3 hours postdose with range from 0.2 to 0.5 hours postdose.

PREGNANCY SECTION.


8.1 Pregnancy. Risk SummaryThere are no adequate and well-controlled studies of VUITY administration in pregnant women to inform drug-associated risk. Oral administration of pilocarpine to pregnant rats throughout organogenesis and lactation did not produce adverse effects at clinically relevant doses. DataHuman DataNo adequate and well-controlled trials of VUITY have been conducted in pregnant women. In retrospective case series of 15 women with glaucoma, patients used ophthalmic pilocarpine either pre-pregnancy, during pregnancy or postpartum. There were no adverse effects observed in patients or in their infants. Animal DataIn embryofetal development studies, oral administration of pilocarpine to pregnant rats throughout organogenesis produced maternal toxicity, skeletal anomalies and reduction in fetal body weight at 90 mg/kg/day (approximately 970-fold higher than the maximum recommended human ophthalmic dose [MRHOD] of 0.015 mg/kg/day, on mg/m2 basis). In peri-/postnatal study in rats, oral administration of pilocarpine during late gestation through lactation increased stillbirths at dose of 36 mg/kg/day (approximately 390-fold higher than the MRHOD). Decreased neonatal survival and reduced mean body weight of pups were observed at >=18 mg/kg/day (approximately 200 times the recommended human daily dose of VUITY).

USE IN SPECIFIC POPULATIONS SECTION.


8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Risk SummaryThere are no adequate and well-controlled studies of VUITY administration in pregnant women to inform drug-associated risk. Oral administration of pilocarpine to pregnant rats throughout organogenesis and lactation did not produce adverse effects at clinically relevant doses. DataHuman DataNo adequate and well-controlled trials of VUITY have been conducted in pregnant women. In retrospective case series of 15 women with glaucoma, patients used ophthalmic pilocarpine either pre-pregnancy, during pregnancy or postpartum. There were no adverse effects observed in patients or in their infants. Animal DataIn embryofetal development studies, oral administration of pilocarpine to pregnant rats throughout organogenesis produced maternal toxicity, skeletal anomalies and reduction in fetal body weight at 90 mg/kg/day (approximately 970-fold higher than the maximum recommended human ophthalmic dose [MRHOD] of 0.015 mg/kg/day, on mg/m2 basis). In peri-/postnatal study in rats, oral administration of pilocarpine during late gestation through lactation increased stillbirths at dose of 36 mg/kg/day (approximately 390-fold higher than the MRHOD). Decreased neonatal survival and reduced mean body weight of pups were observed at >=18 mg/kg/day (approximately 200 times the recommended human daily dose of VUITY).. 8.2 Lactation Risk SummaryThere is no information regarding the presence of pilocarpine in human milk, the effects on the breastfed infants, or the effects on milk production to inform risk of VUITY to an infant during lactation. Pilocarpine and/or its metabolites are excreted in the milk of lactating rats. Systemic levels of pilocarpine following topical ocular administration are low [see Clinical Pharmacology 12.3 ], and it is not known whether measurable levels of pilocarpine would be present in maternal milk following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for VUITY and any potential adverse effects on the breastfed child from VUITY.DataAnimal DataFollowing single oral administration of 14C-pilocarpine to lactating rats, the radioactivity concentrations in milk were similar to those in plasma. 8.4 Pediatric Use. Presbyopia does not occur in the pediatric population. 8.5 Geriatric Use. Clinical studies of VUITY did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience with ophthalmic pilocarpine solutions have not identified overall differences in safety between elderly and younger patients.

WARNINGS AND PRECAUTIONS SECTION.


5 WARNINGS AND PRECAUTIONS. Poor Illumination: Exercise caution in night driving and other hazardous occupations in poor illumination. (5.1)Risk of Retinal Detachment: Rare cases of retinal detachment have been reported with other miotics; patients should be advised to seek immediate medical care with sudden onset of vision loss. (5.2)Iritis: Caution is advised in patients with iritis. (5.3). Poor Illumination: Exercise caution in night driving and other hazardous occupations in poor illumination. (5.1). Risk of Retinal Detachment: Rare cases of retinal detachment have been reported with other miotics; patients should be advised to seek immediate medical care with sudden onset of vision loss. (5.2). Iritis: Caution is advised in patients with iritis. (5.3). 5.1 Poor Illumination. Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear. 5.2 Risk of Retinal Detachment. Rare cases of retinal detachment have been reported with other miotics when used in susceptible individuals and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.. 5.3 Iritis. VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and the lens.. 5.4 Use with Contact Lenses Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.. 5.5 Potential for Eye Injury or Contamination. To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.